The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Update of pathophysiology and management of diabetic kidney disease
Open accessAbstract
Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in patients with diabetes mellitus and the leading cause of end-stage renal disease in the world. The most characteristic marker of DKD is albuminuria, which is associated with renal disease progression and cardiovascular events. Renal hemodynamics changes, oxidative stress, inflammation, hypoxia and overactive renin-angiotensin-aldosterone system (RAAS) are involved in the pathogenesis of DKD, and renal fibrosis plays the key role. Intensified multifactorial interventions, including RAAS blockades, blood pressure and glucose control, and quitting smoking, help to prevent DKD development and progression. In recent years, novel agents are applied for preventing DKD development and progression, including new types of glucose-lowering agents, pentoxifylline, vitamin D analog paricalcitol, pyridoxamine, ruboxistaurin, soludexide, Janus kinase inhibitors and nonsteroidal minerocorticoid receptor antagonists. In this review, recent large studies about DKD are also summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Prospective Study of the Association between Sleep-Disordered Breathing and Hypertension
Peppard, P. E., Young, T., Palta, M., & Skatrud, J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005113421901 · Cited by 4,973
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Williams Textbook of Endocrinology
(2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,711
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Epigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system
Li, Y. C., Kong, J., Wei, M., Chen, Z.-F., Liu, S. Q., & Cao, L.-P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215219 · Cited by 1,625
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Growing roles for the mTOR pathway
Sarbassov, D. D., Ali, S. M., & Sabatini, D. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.009 · Cited by 1,560
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Zatz, R., Dunn, B. R., Meyer, T. W., Anderson, S., Rennke, H. G., & Brenner, B. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112521 · Cited by 1,209
Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes
Forbes, J. M., Coughlan, M. T., & Cooper, M. E. (2008) · Diabetes · doi:10.2337/db08-0057 · Cited by 1,203
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306033 · Cited by 1,030
AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome
Zhang, B. B., Zhou, G., & Li, C. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.012 · Cited by 1,026
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979
Risk Factors for Renal Dysfunction in Type 2 Diabetes
Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R., & for the UKPDS Study Group (2006) · Diabetes · doi:10.2337/db05-1620 · Cited by 927
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengellér, Z., Szabó, C., & Brownlee, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18127 · Cited by 832
The Atg8 and Atg12 ubiquitin‐like conjugation systems in macroautophagy
Geng, J., & Klionsky, D. J. (2008) · EMBO reports · doi:10.1038/embor.2008.163 · Cited by 780
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J. J., & Natarajan, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611192104 · Cited by 699
de Zeeuw, D., Agarwal, R., Amdahl, M., Audhya, P., Coyne, D., Garimella, T., Parving, H.-H., Pritchett, Y., Remuzzi, G., Ritz, E., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61032-x · Cited by 695
Methylation determines fibroblast activation and fibrogenesis in the kidney
Bechtel, W., McGoohan, S., Zeisberg, E. M., Müller, G. A., Kalbacher, H., Salant, D. J., Müller, C. A., Kalluri, R., & Zeisberg, M. (2010) · Nature Medicine · doi:10.1038/nm.2135 · Cited by 639
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes
The DCCT/EDIC Research Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1111732 · Cited by 568
Diabetes and Sleep Disturbances
Resnick, H. E., Redline, S., Shahar, E., Gilpin, A., Newman, A., Walter, R., Ewy, G. A., Howard, B. V., & Punjabi, N. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.702 · Cited by 504
The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease
Anders, H.-J., Andersen, K., & Stecher, B. (2013) · Kidney International · doi:10.1038/ki.2012.440 · Cited by 493
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes
Aronsohn, R. S., Whitmore, H., Van Cauter, E., & Tasali, E. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1423oc · Cited by 453
WANG, P. (1993) · The Lancet · doi:10.1016/0140-6736(93)90816-y · Cited by 446
The Protective Role of Nrf2 in Streptozotocin-Induced Diabetic Nephropathy
Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D., & Zhang, D. D. (2010) · Diabetes · doi:10.2337/db09-1342 · Cited by 440
Self-citationInnate immunity in diabetes and diabetic nephropathy
Wada, J., & Makino, H. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.175 · Cited by 427
The role of the complement system in diabetic nephropathy
Flyvbjerg, A. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.31 · Cited by 397
Pathogenesis of the Podocytopathy and Proteinuria in Diabetic Glomerulopathy
Ziyadeh, F., & Wolf, G. (2008) · Current Diabetes Reviews · doi:10.2174/157339908783502370 · Cited by 383
Antiproteinuric effect of oral paricalcitol in chronic kidney disease
Agarwal, R., Acharya, M., Tian, J., Hippensteel, R. L., Melnick, J. Z., Qiu, P., Williams, L., & Batlle, D. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00755.x · Cited by 377
de Boer, I. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.16 · Cited by 351
Macrophage accumulation in human progressive diabetic nephropathy
NGUYEN, D., PING, F., MU, W., HILL, P., ATKINS, R. C., & CHADBAN, S. J. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00576.x · Cited by 331
Tanasescu, M., Leitzmann, M. F., Rimm, E. B., & Hu, F. B. (2003) · Circulation · doi:10.1161/01.cir.0000066906.11109.1f · Cited by 329
Toma, I., Kang, J. J., Sipos, A., Vargas, S., Bansal, E., Hanner, F., Meer, E., & Peti-Peterdi, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33293 · Cited by 322
Pirfenidone for Diabetic Nephropathy
Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., Francos, B., Sharma, S., Falkner, B., McGowan, T. A., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010101049 · Cited by 319
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy: A Randomized Controlled Trial
House, A. A., Eliasziw, M., Cattran, D. C., Churchill, D. N., Oliver, M. J., Fine, A., Dresser, G. K., & Spence, J. D. (2010) · JAMA · doi:10.1001/jama.2010.490 · Cited by 308
Sodium Intake, ACE Inhibition, and Progression to ESRD
Vegter, S., Perna, A., Postma, M. J., Navis, G., Remuzzi, G., & Ruggenenti, P. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040430 · Cited by 305
Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus
Bell, C. G., Teschendorff, A. E., Rakyan, V. K., Maxwell, A. P., Beck, S., & Savage, D. A. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-33 · Cited by 305
de Zeeuw, D., Coll, B., Andress, D., Brennan, J. J., Tang, H., Houser, M., Correa-Rotter, R., Kohan, D., Lambers Heerspink, H. J., Makino, H., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013080830 · Cited by 302
The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes
Tuttle, K. R., Bakris, G. L., Toto, R. D., McGill, J. B., Hu, K., & Anderson, P. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2686 · Cited by 300
Groop, P.-H., Cooper, M. E., Perkovic, V., Emser, A., Woerle, H.-J., & von Eynatten, M. (2013) · Diabetes Care · doi:10.2337/dc13-0323 · Cited by 294
After the banquet: Mitochondrial biogenesis, mitophagy, and cell survival
Zhu, J., Wang, K. Z., & Chu, C. T. (2013) · Autophagy · doi:10.4161/auto.24135 · Cited by 293
Zhang, Z., Zhang, Y., Ning, G., Deb, D. K., Kong, J., & Li, Y. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803751105 · Cited by 289
Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Potenza, M., Gagliardi, S., Nacci, C., Carratu, M., & Montagnani, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787002853 · Cited by 280
Physical activity/exercise and diabetes mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s73 · Cited by 271
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Mosenzon, O., Leibowitz, G., Bhatt, D. L., Cahn, A., Hirshberg, B., Wei, C., Im, K., Rozenberg, A., Yanuv, I., Stahre, C., et al. (2017) · Diabetes Care · doi:10.2337/dc16-0621 · Cited by 268
The renin-angiotensin-aldosterone system, glucose metabolism and diabetes
Giacchetti, G., Sechi, L. A., Rilli, S., & Carey, R. M. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.02.003 · Cited by 267
Chrysostomou, A., & Becker, G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451215 · Cited by 267
Williams, M. E., Bolton, W. K., Khalifah, R. G., Degenhardt, T. P., Schotzinger, R. J., & McGill, J. B. (2007) · American Journal of Nephrology · doi:10.1159/000108104 · Cited by 253
Rosiglitazone reduces urinary albumin excretion in type II diabetes
Bakris, G., Viberti, G., Weston, W. M., Heise, M., Porter, L. E., & Freed, M. I. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001444 · Cited by 240
Kato, M., Arce, L., Wang, M., Putta, S., Lanting, L., & Natarajan, R. (2011) · Kidney International · doi:10.1038/ki.2011.43 · Cited by 238
Epigenetic Histone Methylation Modulates Fibrotic Gene Expression
Sun, G., Reddy, M. A., Yuan, H., Lanting, L., Kato, M., & Natarajan, R. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010060633 · Cited by 238
Breyer, J. A., Bain, R. P., Evans, J. K., Nahman, N. S., Lewis, E. J., Cooper, M., McGill, J., Berl, T., & The Collaborative Study Group (1996) · Kidney International · doi:10.1038/ki.1996.481 · Cited by 234
Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD
Pergola, P. E., Krauth, M., Huff, J. W., Ferguson, D. A., Ruiz, S., Meyer, C. J., & Warnock, D. G. (2011) · American Journal of Nephrology · doi:10.1159/000327599 · Cited by 233
Lacourcière, Y., Bélanger, A., Godin, C., Hallé, J.-P., Ross, S., Wright, N., & Marion, J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00224.x · Cited by 229
Jacobsen, P., Andersen, S., Rossing, K., Jensen, B. R., & Parving, H.-H. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00940.x · Cited by 226
Navarro-González, J. F., Mora-Fernández, C., Muros de Fuentes, M., Chahin, J., Méndez, M. L., Gallego, E., Macía, M., del Castillo, N., Rivero, A., Getino, M. A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010012 · Cited by 221
Yoh, K., Hirayama, A., Ishizaki, K., Yamada, A., Takeuchi, M., Yamagishi, S., Morito, N., Nakano, T., Ojima, M., Shimohata, H., et al. (2008) · Genes to Cells · doi:10.1111/j.1365-2443.2008.01234.x · Cited by 207
Ahmad, J., Siddiqui, M. A., & Ahmad, H. (1997) · Diabetes Care · doi:10.2337/diacare.20.10.1576 · Cited by 198
Taler, S. J., Agarwal, R., Bakris, G. L., Flynn, J. T., Nilsson, P. M., Rahman, M., Sanders, P. W., Textor, S. C., Weir, M. R., & Townsend, R. R. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.03.018 · Cited by 198
Mitochondrial Hormesis and Diabetic Complications
Sharma, K. (2015) · Diabetes · doi:10.2337/db14-0874 · Cited by 193
de Zeeuw, D., Anzalone, D. A., Cain, V. A., Cressman, M. D., Heerspink, H. J. L., Molitoris, B. A., Monyak, J. T., Parving, H.-H., Remuzzi, G., Sowers, J. R., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70246-3 · Cited by 167
Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease
He, J., Xu, Y., Koya, D., & Kanasaki, K. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0781-0 · Cited by 167
Role of nitric oxide in diabetic nephropathy
Prabhakar, S. S. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2004.04.005 · Cited by 167
Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164
Deshpande, S. D., Putta, S., Wang, M., Lai, J. Y., Bitzer, M., Nelson, R. G., Lanting, L. L., Kato, M., & Natarajan, R. (2013) · Diabetes · doi:10.2337/db13-0305 · Cited by 161
Lin, S., Chen, R., Chen, Y., Chiang, W., Lai, C., Wu, K., & Tsai, T. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005040435 · Cited by 156
Self-citationJAK inhibition in the treatment of diabetic kidney disease
Brosius, F. C., Tuttle, K. R., & Kretzler, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4021-5 · Cited by 145
The Renin-Angiotensin System and Diabetic Nephropathy
Gurley, S. B., & Coffman, T. M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.009 · Cited by 144
Salem, M. A., AboElAsrar, M. A., Elbarbary, N. S., ElHilaly, R. A., & Refaat, Y. M. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-47 · Cited by 140
Jin, Y., Liu, S., Ma, Q., Xiao, D., & Chen, L. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.037 · Cited by 134
Exercise and inflammation-related epigenetic modifications: focus on DNA methylation.
Horsburgh, S., Robson-Ansley, P. J., Adams, R. C. M., & Smith, C. (2015) · PubMed · Cited by 130
Kato, M. V., Dang, V., Wang, M., Park, J. T., Deshpande, S., Kadam, S., Mardiros, A., Zhan, Y., Oettgen, P., Putta, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003389 · Cited by 130
Expression of hypoxia-inducible transcription factors in developing human and rat kidneys
Bernhardt, W. M., Schmitt, R., Rosenberger, C., Münchenhagen, P., Gröne, H., Frei, U. A., Warnecke, C., Bachmann, S., Wiesener, M. S., Willam, C., et al. (2005) · Kidney International · doi:10.1038/sj.ki.5000062 · Cited by 124
Esnault, V. L. M., Ekhlas, A., Delcroix, C., Mg, M., & Nguyen, J. (2004) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004060505 · Cited by 122
How to Protect the Kidney in Diabetic Patients: With Special Reference to IDDM
Mogensen, C. (1997) · Diabetes · doi:10.2337/diab.46.2.s104 · Cited by 120
Li, Z., Liu, X., Wang, B., Nie, Y., Wen, J., Wang, Q., & Gu, C. (2016) · Nephrology · doi:10.1111/nep.12831 · Cited by 118
Chen, P.-M., Lai, T., Chen, P. Y., Lai, C. F., Yang, S., Wu, V., Chiang, C., Kao, T. W., Huang, J., Chiang, W., et al. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.042 · Cited by 115
Self-citationThe role of autophagy in unilateral ureteral obstruction rat model
KIM, W., NAM, S. A., SONG, H. C., KO, J. S., PARK, S. H., KIM, H. L., CHOI, E. J., KIM, Y., KIM, J., & KIM, Y. K. (2012) · Nephrology · doi:10.1111/j.1440-1797.2011.01541.x · Cited by 108
Back to the future: glomerular hyperfiltration and the diabetic kidney
Tuttle, K. R. (2017) · Diabetes · doi:10.2337/dbi16-0056 · Cited by 108
Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up
Heneghan, H., Cetin, D. C., Navaneethan, S. D., Orzech, N., Brethauer, S. A., & Schauer, P. R. (2012) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2012.08.016 · Cited by 107
Sourris, K. C., & Forbes, J. M. (2009) · Current Drug Targets · doi:10.2174/138945009787122905 · Cited by 102
Bakris, G. L., Ruilope, L. M., McMorn, S. O., Weston, W. M., Heise, M. A., Freed, M. I., & Porter, L. E. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000244955.39491.88 · Cited by 101
Palmer, A. J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R. K., Gabriel, S., Carita, P., Rodby, R. A., de Zeeuw, D., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1897 · Cited by 97
Kidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye Disease
Tuttle, K. R., McGill, J. B., Haney, D. J., Lin, T. E., & Anderson, P. W. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00840207 · Cited by 94
Short-Term Changes after a Weight Reduction Intervention in Advanced Diabetic Nephropathy
Friedman, A. N., Chambers, M., Kamendulis, L. M., & Temmerman, J. C. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010413 · Cited by 91
Andrésdóttir, G., Jensen, M. L., Carstensen, B., Parving, H., Rossing, K., Hansen, T. W., & Rossing, P. R. (2014) · Diabetes Care · doi:10.2337/dc13-2036 · Cited by 84
Advanced Glycation Endproducts in Nondiabetic Patients With Obstructive Sleep Apnea
Tan, K. C. B., Chow, W.-S., Lam, J. C. M., LAM, B. K., Bucala, R., Betteridge, J. D., & Ip, M. (2006) · SLEEP · doi:10.1093/sleep/29.3.329 · Cited by 79
Phisitkul, K., Hegazy, K., Chuahirun, T., Hudson, C., Wesson, D. E., Simoni, J. M., & Rajab, H. (2008) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318156b799 · Cited by 75
Leong, W. B., Jadhakhan, F., Taheri, S., Thomas, G. N., & Adab, P. (2016) · SLEEP · doi:10.5665/sleep.5432 · Cited by 71
von Scholten, B. J., Hansen, T. W., Goetze, J. P., Persson, F., & Rossing, P. R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.04.004 · Cited by 69
Imamura, S., Hirai, K., & Hirai, A. (2013) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.231.57 · Cited by 67
β-Arrestins promote podocyte injury by inhibition of autophagy in diabetic nephropathy
Liu, J., Li, Q. X., Wang, X. J., Zhang, C., Duan, Y. Q., Wang, Z. Y., Zhang, Y., Yu, X., Li, N. J., Sun, J. P., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.89 · Cited by 62
Huang, Y., Lin, K., Jiang, Y., Chang, C., Chung, C., Chuang, L., Tai, T., Ho, L.-T., & Shin, S. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.09.006 · Cited by 58
Tufescu, A., Kanazawa, M., Ishida, A., Lu, H., Sasaki, Y., Ootaka, T., Sato, T., & Kohzuki, M. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f2450b · Cited by 55
Fujihara, C. K., Padilha, R. M., & Zatz, R. (1992) · Diabetes · doi:10.2337/diab.41.3.286 · Cited by 44
Pentoxifylline: A potential therapy for chronic kidney disease
Lin, S., Chen, Y., Chiang, W., Tsai, T., & Wy, C. (2004) · Nephrology · doi:10.1111/j.1440-1797.2004.00267.x · Cited by 40
Targeting skeletal muscle mitochondria to prevent type 2 diabetes in youth
Gordon, J. W., Dolinsky, V. W., Mughal, W., Gordon, G. R., & McGavock, J. (2015) · Biochemistry and Cell Biology · doi:10.1139/bcb-2015-0012 · Cited by 31
Chen, P.-M., Lai, T., Chen, P., Lai, C., Wu, V., Chiang, W., Chen, Y., Wu, K., & Tsai, T. (2014) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2014.01.002 · Cited by 31
Self-citationAldosterone, a vasculotoxic agent--novel functions for an old hormone
Ritz, E., & Tomaschitz, A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp206 · Cited by 30
Xu, X., Luo, P., Wang, Y., Cui, Y., & Miao, L. (2013) · Journal of International Medical Research · doi:10.1177/0300060513477004 · Cited by 30
Pallayová, M., Banerjee, D., & Taheri, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.007 · Cited by 29
Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review
Zhang, Y., Xing, J., Mu, X., Wang, H., Zhang, L., Zhao, Y., & Li, R. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s87973 · Cited by 27
Chen, C., Wu, H., Wang, C.-L., Yang, F., Wu, P., Hung, S., Kan, W., Yang, C., Chiang, C., Huang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep26539 · Cited by 26
Huang, C., Ting, W., Lo, F., Tsai, J.-D., Sun, F., Chan, C.-I., Chiang, Y.-T., Lin, C., Cheng, B.-W., Wu, Y., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2017.09.015 · Cited by 23
Mathiesen, E. R., Feldt‐Rasmussen, B., Hommel, E. E., Deckert, T., & Parving, H. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.286 · Cited by 19
Cited by
Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
Jung, C.-Y., & Yoo, T.-H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0329 · Cited by 262
Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06870520 · Cited by 234
Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments
Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231
Chaudhuri, A., Ghanim, H., & Arora, P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14601 · Cited by 120
“Renal ischaemia further enhances inflammation via increased infiltration of neutrophils and macrophages, whereas activated complement facilitates the recruitment of leukocytes and mast cells in the kidney.(23) Activation of the RAS is also implicated in the promotion of kidney fibrosis.”
BackgroundInfluentialChen, J.-J., Wu, C.-Y., Jenq, C.-C., Lee, T.-H., Tsai, C.-Y., Tu, H.-T., Huang, Y.-T., Yen, C.-L., Yen, T.-H., Chen, Y.-C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.1169 · Cited by 82
Metadata
- Authors
- Lin, Y.-C., Chang, Y.-H., Yang, S.-Y., Wu, K.-D., & Chu, T.-S.
- Venue
- Journal of the Formosan Medical Association
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 117
- Issue
- 8
- Pages
- 662-675
- ISSN
- 0929-6646 (ISSN-L)
- OpenAlex
- W2791990516
- Cited by
- 562
- References
- 129
- FWCI
- 27.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.